Research summary, original research, 2017

Reduction of Radiation Exposure Using Dynamic Trace Digital Angiography and Spot Fluoroscopy During Adrenal Venous Sampling

Morita S, Endo K, Suzaki S, Ishizaki U, Yamazaki H, Nishina Y, et al.. Cardiovascular and interventional radiology. 2017

Read the original paper

In plain language

In 22 adrenal venous sampling procedures, dynamic trace digital angiography and spot fluoroscopy roughly halved measured patient dose and operator radiation exposure compared with conventional digital subtraction angiography (DSA), with comparable image quality. The study was small.

At a glance

Type of study
Original research
Who was studied
Patients, Interventional radiologists
Size
n = 22 patients
Summary based on
the abstract

What it found

  • Operator radiation exposure was roughly halved with DTDA and spot fluoroscopy compared with conventional DSA with collimation.

    Key figures: 17.1 ± 14.8 vs. 36.6 ± 21.7 μSv, p = 0.013

  • Total dose-area product was significantly lower with DTDA and spot fluoroscopy.

    Key figures: 38.6 ± 25.9 vs. 88.2 ± 53.6 Gy cm2, p = 0.006

  • Acquisition dose-area product (DAP) with DTDA was much lower than with conventional DSA.

    Key figures: 5.3 ± 3.7 vs. 29.1 ± 20.1 Gy cm2, p < 0.001

  • Patient peak skin dose was significantly lower with DTDA and spot fluoroscopy.

    Key figures: 403 ± 340 vs. 771 ± 416 mGy, p = 0.030

  • Image quality of DTDA was equivalent to DSA and higher than digital angiography.

    Key figures: 4.4 ± 0.6 vs. 4.3 ± 0.8, p = 0.651; vs. 3.8 ± 0.9, p = 0.011

Limits to keep in mind

Very small two-group comparison (11 patients each) with no stated randomization or design details, in a single procedure type; operator dose is a dosimeter measurement, not a health outcome.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.